Kadmon Holdings Inc (KDMN) Expected to Announce Earnings of -$0.34 Per Share

Equities analysts expect that Kadmon Holdings Inc (NYSE:KDMN) will report earnings of ($0.34) per share for the current quarter, Zacks reports. Two analysts have made estimates for Kadmon’s earnings, with estimates ranging from ($0.46) to ($0.26). Kadmon reported earnings of ($0.50) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 32%. The firm is expected to report its next quarterly earnings report on Wednesday, March 28th.

On average, analysts expect that Kadmon will report full year earnings of ($1.61) per share for the current fiscal year, with EPS estimates ranging from ($1.71) to ($1.51). For the next fiscal year, analysts forecast that the business will post earnings of ($1.43) per share, with EPS estimates ranging from ($1.89) to ($1.08). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Kadmon.

Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.04). The firm had revenue of $2.28 million during the quarter, compared to the consensus estimate of $5.69 million. Kadmon’s quarterly revenue was down 60.0% compared to the same quarter last year. During the same period last year, the firm earned ($4.24) EPS.

KDMN has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a report on Friday, November 17th. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Friday. Finally, WBB Securities cut Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price objective for the company. in a report on Monday, October 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $8.65.

A number of institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its holdings in Kadmon by 17.0% during the second quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares during the period. Goldman Sachs Group Inc. bought a new position in Kadmon during the second quarter worth about $114,000. Bank of New York Mellon Corp bought a new position in Kadmon during the third quarter worth about $119,000. Old West Investment Management LLC bought a new position in Kadmon during the third quarter worth about $169,000. Finally, AE Wealth Management LLC grew its holdings in Kadmon by 33.6% during the third quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock worth $1,083,000 after purchasing an additional 81,226 shares during the period. Institutional investors and hedge funds own 51.90% of the company’s stock.

Shares of Kadmon (NYSE KDMN) traded up $0.16 during midday trading on Friday, hitting $4.03. The stock had a trading volume of 3,628,872 shares, compared to its average volume of 1,014,713. The company has a market cap of $304.35 and a PE ratio of -2.30. Kadmon has a 12 month low of $2.05 and a 12 month high of $5.07.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://ledgergazette.com/2018/01/12/kadmon-holdings-inc-kdmn-expected-to-announce-earnings-of-0-34-per-share.html.

Kadmon Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply